Detail akcie ADMA Biologics online

Business Summary: ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Financial Summary: BRIEF: For the six months ended 30 June 2024, ADMA Biologics Inc revenues increased 62% to $189.1M. Net income totaled $49.9M vs. loss of $13.2M. Revenues reflect ADMA BioManufacturing segment increase of 70% to $186.3M, Corporate segment increase of 1% to $72K, United States segment increase of 65% to $180.7M, International segment increase of 8% to $8.3M.